A pilot study of efficacy and safety of aprepitant with chemoradiotherapy involving weekly cisplatin in patients with cervical cancer

INTERVENTION: aprepitant observation CONDITION: cervical cancer PRIMARY OUTCOME: The proportion of nausea, vomiting, fatigue and headache as graded by CTCAE v.4.0 with or without aprepitant. SECONDARY OUTCOME: 1. the evaluation of QOL using FLIE.; 2. the proportion of patients who completed more than 5 courses.; 3. comparison of 6B‐OHF in urine.; 4. adverse events. INCLUSION CRITERIA: 1. patients with chemoradiotherapy containinig weekly cisplatin in FIGO stage IB2, II, III, IVA cervical cancer. 2. cisplatin: 40mg/m2/week. 3. Performance Status: 0‐2 4. Adequate organ functions. 5. patients who can mention a diary. 6. patients who have signed to an approved informed consent.